These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27999019)

  • 41. Disease caused by non-tuberculous mycobacteria: diagnostic procedures and treatment evaluation in the North of Buenos Aires Province.
    Imperiale B; Zumárraga M; Gioffré A; Di Giulio B; Cataldi A; Morcillo N
    Rev Argent Microbiol; 2012; 44(1):3-9. PubMed ID: 22610284
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Brown-Elliott BA; Wallace RJ
    J Clin Microbiol; 2017 Jun; 55(6):1747-1754. PubMed ID: 28330892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Introducing the new BTS Guideline: Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
    Haworth CS; Floto RA
    Thorax; 2017 Nov; 72(11):969-970. PubMed ID: 29054887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: a Korean perspective.
    Koh WJ; Kwon OJ; Lee KS
    J Korean Med Sci; 2005 Dec; 20(6):913-25. PubMed ID: 16361797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection.
    Valour F; Perpoint T; Sénéchal A; Kong XF; Bustamante J; Ferry T; Chidiac C; Ader F;
    Emerg Infect Dis; 2016 Jun; 22(6):1124-1126. PubMed ID: 27192204
    [No Abstract]   [Full Text] [Related]  

  • 46. Disseminated Mycobacterium gordonae infection in a child with cystic fibrosis.
    Verma N; Spencer D
    Pediatr Pulmonol; 2012 May; 47(5):517-8. PubMed ID: 22028301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of infections caused by nontuberculous mycobacteria.
    Esteban J; Navas E
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Nov; 36(9):586-592. PubMed ID: 29217094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary Mycobacteriosis in a Patient Receiving Chronic Methotrexate Treatment.
    Dal Molín-Veglia MA; Sánchez-Martínez F; Fernández-Alarza AF; Domínguez-Álvarez M
    Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):225-226. PubMed ID: 29108758
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
    Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
    Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013.
    Morimoto K; Hasegawa N; Izumi K; Namkoong H; Uchimura K; Yoshiyama T; Hoshino Y; Kurashima A; Sokunaga J; Shibuya S; Shimojima M; Ato M; Mitarai S
    Ann Am Thorac Soc; 2017 Jan; 14(1):49-56. PubMed ID: 27788025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Skin disease and nontuberculous atypical mycobacteria.
    Palenque E
    Int J Dermatol; 2000 Sep; 39(9):659-66. PubMed ID: 11044189
    [No Abstract]   [Full Text] [Related]  

  • 53. Tedizolid: a service evaluation in a large UK teaching hospital.
    York JA; Adams K; Cullen L; Delahay J; Ivan M; Lillie PJ; MacLachlan L; Barlow G
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):397-405. PubMed ID: 32851509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
    Douros A; Grabowski K; Stahlmann R
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mixed pulmonary infection with three types of nontuberculous mycobacteria.
    Kurahara Y; Tachibana K; Tsuyuguchi K; Suzuki K
    Intern Med; 2013; 52(4):507-10. PubMed ID: 23411711
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of nontuberculous mycobacterial (NTM) lung disease.
    Philley JV; Griffith DE
    Semin Respir Crit Care Med; 2013 Feb; 34(1):135-42. PubMed ID: 23460013
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pulmonary nocardiosis treated with tedizolid.
    Giménez-Arufe V; Gutiérrez-Urbón JM; Blanco-Aparicio M; Míguez-Rey E; Martín-Herranz MI
    Farm Hosp; 2019 Nov; 43(6):208-210. PubMed ID: 31705645
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993-2011.
    de Mello KG; Mello FC; Borga L; Rolla V; Duarte RS; Sampaio EP; Holland SM; Prevots DR; Dalcolmo MP
    Emerg Infect Dis; 2013 Mar; 19(3):393-9. PubMed ID: 23745217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ethambutol-induced bullous skin lesions in
    Kollipara VK; Horowitz M; Lantz J; Nagy-Agren S
    Int J Mycobacteriol; 2022; 11(1):120-122. PubMed ID: 35295035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mycobacterium brisbanense lung infection facilitated by steroid induced adrenal insufficiency.
    Gynthersen R; Qvist T; Andersen ÅB; Katzenstein TL
    APMIS; 2019 Feb; 127(2):106-108. PubMed ID: 30585355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.